Subject:
- Active Substance: Crizanlizumab
- Name: Adakveo
- Therapeutic area: Haematology - Hemostaseology
- Pharmaceutical company: Novartis Pharma GmbH
Time table:
- Publication of project plan: 28.07.2020
- Publication of final assessment: 25.11.2020
Assessment information:
- Title: Crizanlizumab for the prevention of recurrent vaso-occlusive crises in sickle cell disease patients aged 16 years and over
- Author/Co-Author: ZIN (Netherlands), AEMPS (Spain)
- Dedicated Reviewers: HAS (France), NICE (UK), JAZMP (Slovenia)